Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofutriben + Prednisolone in PMR
NCT06281236Phase 1Terminated
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of clofutriben in polymyalgia rheumatica (PMR), sponsored by Sparrow Pharmaceuticals. Primary endpoints: Erythrocyte sedimentation rate at Day 28, C-reactive protein at Day 28 and 1 more. Started Feb 2022; status: terminated.
02
Drugs
clofutriben
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT06281236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281236.